Kelly Smith, PA
Medical · Moundsville, WVNPI 1780673772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 223 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$760
- AbbVie$654
- Novo Nordisk$480
- Lilly USA, LLC$480
- Boehringer Ingelheim$390
- GSK$197
- plus $927 from 16 others
What the payments were for
- Food & beverage$3,888100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $760 |
| AbbVie(2 entities) | 37 | $654 |
| Novo Nordisk | 30 | $480 |
| Lilly USA, LLC | 33 | $480 |
| Boehringer Ingelheim | 23 | $390 |
| GSK | 13 | $197 |
| Johnson & Johnson(2 entities) | 12 | $152 |
| Sanofi-aventis U.S. LLC | 9 | $136 |
| Amgen | 6 | $103 |
| Pfizer | 7 | $100 |
| Alkermes, Inc. | 4 | $100 |
| Blueprint Medicines Corporation | 3 | $61 |
| Exact Sciences | 2 | $48 |
| Azurity Pharmaceuticals, Inc. | 3 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Averitas Pharma Inc. | 1 | $36 |
| Medtronic | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$3,888 in reported general payments places this provider in the 80th percentile of 233 medical providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 72 | $64,019 |
| OzempicSemaglutide | 50 | $57,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $40,184 |
| JanuviaSitagliptin Phosphate | 37 | $38,655 |
| EliquisApixaban | 38 | $37,224 |
| TrulicityDulaglutide | 35 | $34,711 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $34,526 |
| MounjaroTirzepatide | 21 | $23,507 |
| TradjentaLinagliptin | 33 | $21,340 |
| FarxigaDapagliflozin Propanediol | 22 | $19,439 |
| XareltoRivaroxaban | 20 | $16,461 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $14,492 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 22 | $10,587 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $10,087 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $7,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $390 | $95,946127 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $480 | $58,21856 claims |
| Novo NordiskOzempic | $480 | $57,95850 claims |
| GSKTrelegy Ellipta | $197 | $40,18451 claims |
| PfizerEliquis | $100 | $37,22438 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $136 | $34,52629 claims |
| AstraZenecaFarxiga | $760 | $19,43922 claims |
| Johnson & JohnsonXarelto | $152 | $16,46120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 233 medical providers in West Virginia.
Other medical in Moundsville
- Katherine BoggsSouth Charleston$46K
- Lowell LarewMorgantown$31K
- Katie CarpenterSouth Charleston$26K
- Lauren DillonBeckley$18K
- Angela HagerFarmington$16K
- Brandon CaragCharleston$16K
- Scott EthridgeCharleston$16K
- Kellie HanselSouth Charleston$12K
- Matthew MaynardElkins$10K
- Mohammad YousafCharleston$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.